[Drug Therapy and Radiotherapy in Graves' Orbitopathy]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2011 May 19

PMID 21590352

Authors

F Beisse

W A Lagreze

M Schmucker

Affiliations

Soon will be listed here.

Abstract

Drug therapy and radiotherapy in Graves' orbitopathy (GO) aim mainly at the inherent soft tissue inflammation. A timely and sustained anti-inflammatory therapy not only alleviates the current symptoms but particularly intends to limit the degree of permanent alterations. It is indicated in active GO of moderate or higher severity. Pharmacologically, glucocorticoids and if appropriate other immunosuppressive agents, such as cyclosporine are given. Adverse effects can complicate the treatment. Retrobulbar irradiation is applied against diplopia due to eye muscle involvement during the active phase.

References

Kahaly G, Pitz S, Hommel G, Dittmar M . Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005; 90(9):5234-40. DOI: 10.1210/jc.2005-0148. View

Gerding M, Terwee C, Dekker F, Koornneef L, Prummel M, Wiersinga W . Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1998; 7(6):885-9. DOI: 10.1089/thy.1997.7.885. View

Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S . Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007; 156(1):33-40. DOI: 10.1530/eje.1.02325. View

Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W . Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986; 16(5):415-22. DOI: 10.1111/j.1365-2362.1986.tb01016.x. View

Kahaly G, Pitz S, Muller-Forell W, Hommel G . Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol. 1996; 106(2):197-202. PMC: 2200583. DOI: 10.1046/j.1365-2249.1996.d01-854.x. View

Perros P, Weightman D, CROMBIE A, Kendall-Taylor P . Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990; 122(1):8-12. DOI: 10.1530/acta.0.1220008. View

Uddin J, Davies P . Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002; 109(6):1183-7. DOI: 10.1016/s0161-6420(02)01041-2. View

Prummel M, Terwee C, Gerding M, Baldeschi L, Mourits M, Blank L . A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004; 89(1):15-20. DOI: 10.1210/jc.2003-030809. View

Bartalena L, Marcocci C, Chiovato L, LADDAGA M, Lepri G, Andreani D . Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983; 56(6):1139-44. DOI: 10.1210/jcem-56-6-1139. View

10.

Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J, Blomgren H . Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992; 326(26):1733-8. DOI: 10.1056/NEJM199206253262603. View

11.

Wabbels B, Forl M . [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]. Ophthalmologe. 2007; 104(9):771-6. DOI: 10.1007/s00347-007-1592-z. View

12.

Kahaly G, Lieb W, Muller-Forell W, Mainberger M, Beyer J, Vollmar J . Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study. Acta Endocrinol (Copenh). 1990; 122(1):13-21. DOI: 10.1530/acta.0.1220013. View

13.

Leer J, Van Houtte P, Seegenschmiedt H . Radiotherapy of non-malignant disorders: where do we stand?. Radiother Oncol. 2007; 83(2):175-7. DOI: 10.1016/j.radonc.2007.04.008. View

14.

Bartalena L, Marcocci C, Tanda M, Manetti L, DellUnto E, Bartolomei M . Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998; 129(8):632-5. DOI: 10.7326/0003-4819-129-8-199810150-00010. View

15.

Sterker I, Tegetmeyer H, Papsdorf K, Fuhrer-Sakel D . Effect of combined intravenous glucocorticoids and orbital radiotherapy in restoring driving competency in patients with Graves' orbitopathy. Horm Metab Res. 2009; 41(5):391-6. DOI: 10.1055/s-0028-1128141. View

16.

Prummel M, Mourits M, Berghout A, Krenning E, van der Gaag R, Koornneef L . Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989; 321(20):1353-9. DOI: 10.1056/NEJM198911163212002. View

17.

Gorman C, Garrity J, Fatourechi V, Bahn R, Petersen I, Stafford S . A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001; 108(9):1523-34. DOI: 10.1016/s0161-6420(01)00632-7. View

18.

Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits M, Wiersinga W . Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid. 2007; 17(4):357-62. DOI: 10.1089/thy.2006.0267. View

19.

Paridaens D, van den Bosch W, van der Loos T, Krenning E, van Hagen P . The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2004; 19(12):1286-9. DOI: 10.1038/sj.eye.6701768. View

20.

Kalmann R, Mourits M . Prevalence and management of elevated intraocular pressure in patients with Graves' orbitopathy. Br J Ophthalmol. 1999; 82(7):754-7. PMC: 1722671. DOI: 10.1136/bjo.82.7.754. View